BELLEVUE, WA, April 10 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) announced today that data from preclinical studies of PX-478, pharmacodynamic studies of PX-12 and preclinical studies of PX-866 will be presented at the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego April 12-16, 2008.
Oncothyreon is currently conducting a Phase 1 clinical trial of PX-478
in patients with advanced metastatic cancer and a Phase 2 trial of PX-12 in
patients with advanced pancreatic cancer. PX-866 is expected to enter a
Phase 1 trial in patients with advanced cancers in the second quarter of
Details regarding these abstracts are as follows:
- Molecular-genetic image guided studies of the antitumor HIF-1alpha
inhibitor PX-478 in combination with radiation
Abstract # 2566, Session: Novel Mechanisms of Drug Action
Presentation: Monday, April 14, 2008, 2:55 p.m. to 3:10 p.m. P.T.
- HIF-1alpha antagonism by PX-478 inhibits progression and spread of
orthotopic human small cell lung cancer and lung adenocarcinoma in
Abstract # 1440, Session: mTOR/Akt/PI3K Inhibitors and
Vascular/Hypoxia Targeting Agents
Poster session: Sunday, April 13, 2008, 1:00 p.m. to
5:00 p.m. P.T.
- Pharmacodynamic evaluation of plasma thioredoxin-1 for patient
enrichment of PX-12 clinical trials
Abstract # 4453, Session: Molecular Signatures and Proteomic
Poster Session: Tuesday, April 15, 2008, 1:00 p.m. to
5:00 p.m. P.T.
- Cellular and in vivo
|SOURCE Oncothyreon Inc.|
Copyright©2008 PR Newswire.
All rights reserved